-85%

est. 2Y upside i

HealthcareSeed

Trilobio is building the hardware and software to fully automate biology labs, transforming the fields of synthetic and molecular biology.

Rank

#450

Sector

Biotechnology, Lab Automation

Est. Liquidity

~6Y

Data Quality

Data: Medium

Trilobio presents a strong upside opportunity due to its disruptive 'lab-in-a-box' platform targeting a large and growing market in synthetic biology and lab automation.

Last updated: March 10, 2026

Bull (20%)+400%

Trilobio's 'lab-in-a-box' platform gains rapid adoption, particularly in academic and smaller biotech labs, driven by its affordability and ease of use. This market traction and a strong product roadmap, including expansion of its protocol app store, push revenue to $50M+ by 2028 and justify a Series B valuation of $225M, representing a 400% upside from the current estimated valuation.

Base (45%)+150%

Trilobio successfully executes its initial go-to-market strategy, securing key partnerships and steadily growing its customer base, demonstrating increased throughput and data production. Revenue reaches $25M by 2028, leading to a Series A/B valuation of $112.5M, a 150% upside, as it continues to build out its platform and expand its protocol app store.

Bear (35%)-80%

Intense competition from well-funded incumbents like Ginkgo Bioworks and established lab automation giants (e.g., Thermo Fisher Scientific) slows Trilobio's market penetration. The ongoing trade secret dispute also causes operational delays and reputational damage. Revenue growth stalls, leading to a down round or acquisition at a significantly lower valuation of $9M, resulting in an 80% downside for common shareholders due to liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $11M in liquidation preferences, representing 24.4% of the estimated $45M current valuation, ahead of common stock holders.

Dilution Risk

high

As a seed-stage company, significant dilution is expected over multiple future funding rounds (Series A, B, C, etc.) before a potential liquidity event.

Secondary Liquidity

none

Given the early seed stage, there is no active secondary market or tender offers for Trilobio's equity.

Other — 2 roles

View all 2 open roles at Trilobio →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Trilobio's data — designed to show you've done your homework.

  • 1

    “How is Trilobio planning to differentiate and defend its market position against established lab automation giants like Thermo Fisher Scientific and Agilent, especially as they might develop more user-friendly or affordable solutions?”

  • 2

    “Given the positive pilot data showing increased throughput and data production, what are the key metrics and milestones Trilobio is focused on achieving in the next 12-18 months to demonstrate scalable growth and prepare for a Series A round?”

  • 3

    “With $11M raised to date and an estimated $45M valuation, what is the company's strategy for future funding rounds, and how does it plan to manage potential dilution for early employees holding common stock?”

Community

Valuation Sentiment

Our model estimates -85% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.